Earnings call briefThird-quarter 2026
Eli Lilly LLY
Eli Lilly expects 2027 volume growth to more than offset price headwind
Chief Financial Officer Lucas E. Montarce said 2026 revenue included approximately $2 billion of one-time items the company does not expect to recur.
GetSignal
Free on iOS and Android
On its third-quarter call, Chief Financial Officer Lucas E. Montarce said the company expects net realized price to be a headwind in 2027, more than offset by volume growth. He said U.S. revenue in 2027 is expected to benefit from sustained incretin volume growth, the full-year impact of Medicare GLP-1 bridge access, and the launch of Foundayo in type 2 diabetes.
Quotes from the call
“Consistent with previous years, we expect net realized price to be a headwind more than offset by volume growth.”
Key facts from the call
- Expected 2027 net realized price
- Headwind more than offset by volume growth
- 2026 one-time items in revenue
- Approximately $2 billion
Source: Eli Lilly's third-quarter 2026 earnings call, October 29, 2026.
Written by GetSignal with AI from the company's earnings call.
Not investment advice.